Actively Recruiting
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Led by EMD Serono Research & Development Institute, Inc. · Updated on 2026-05-08
52
Participants Needed
11
Research Sites
127 weeks
Total Duration
On this page
Sponsors
E
EMD Serono Research & Development Institute, Inc.
Lead Sponsor
M
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
CONDITIONS
Official Title
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with locally advanced or metastatic soft tissue sarcoma (STS) that has progressed after at least one prior anthracycline-containing systemic therapy
- Participants with resectable STS who had surgery at least 4 weeks before study start and have residual disease
- Participants with glioblastoma, IDH-wildtype, who progressed after only one prior therapy and relapsed at least 3 months after radiotherapy
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Adequate blood, liver, and kidney function as defined by the study protocol
- Other inclusion criteria as defined by the protocol
You will not qualify if you...
- History of malignancy other than STS or glioblastoma within 3 years before enrollment, except certain skin cancers, cervical carcinoma in situ, benign prostate conditions, or malignancies considered cured with minimal recurrence risk
- For STS participants only: history of brain metastasis, leptomeningeal metastasis, or spinal cord compression
- Other exclusion criteria as defined by the study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc
New York, New York, United States, 10022
Withdrawn
3
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
4
UZ Leuven
Leuven, Belgium
Actively Recruiting
5
Institut Bergonié - Service d'Oncologie Médicale
Bordeaux, France
Actively Recruiting
6
Centre Oscar Lambret - cancerologie generale
Lille, France
Actively Recruiting
7
Centre Leon Berard - Service d'Oncologie Medicale
Lyon, France
Actively Recruiting
8
Centre Antoine Lacassagne - Service d'Hématologie Oncologie
Nice, France
Actively Recruiting
9
National Cancer Center Hospital
Chūōku, Japan
Actively Recruiting
10
Universitaetsspital Zuerich - Klinik fuer Neurologie
Zurich, Switzerland, 8091
Actively Recruiting
11
Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey)
Sutton, Surrey, United Kingdom, SM2 5PT
Actively Recruiting
Research Team
U
US Medical Information
CONTACT
C
Communication Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here